Evidence map›Paper›PMID 27813499›Full record

ArticleOncotarget2016

Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma.

Hai-Zhou Liu, Wei Deng, Ji-Lin Li, Ya-Mei Tang, Li-Tu Zhang, Ying Cui, Xin-Qiang Liang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hai-Zhou LiuDepartment of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Wei DengDepartment of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Ji-Lin LiDepartment of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Ya-Mei TangDepartment of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Li-Tu ZhangDepartment of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Ying CuiDepartment of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Xin-Qiang LiangDepartment of Medical Research, The Affiliated Tumor Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, P.R. China.
Tumor Hospital of Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the levels of target lymphocyte subsets in peripheral blood lymphocyte samples from patients with hepatocellular carcinoma (HCC). A total of 715 high-risk patients with primary HCC were recruited in Guangxi, China as the case group. The control group included 100 patients who received health examinations at the same hospital during the same period. Fasting elbow venous blood (10 mL) was collected from each participant, and flow cytometry was used to detect the levels of NK cells and CD3+, CD4+ and CD19+ T cells in peripheral blood samples. All included patients with prmary HCC were treated by surgical resection, and followed up for one year. The levels of CD19+ and NK cells were lower in cases than in controls (both P < 0.05). In addition, the level of CD8+ cells was greater in the case group than in the control group (P < 0.05). In the high-HCC-risk population, CD8+, CD19+ and NK cell levels all differed between male and female patients, patients in TNM stages I-II and stages III-IV, patients with and without extrahepatic metastasis, and patients with and without HBV infection (all P < 0.05). After follow-up, detected recurrence and survival rate was 33.71% and 83.64%, respectively. CD8+ levels was reduced following surgical resection, whereas the levels of CD19+ and NK cells were increased (all P < 0.05). In conclusion, altered levels of CD8+, CD19+ and NK cell levels may be used as reference values for monitoring immune function in certain populations with high HCC risk, and as potential evidence for the clinical diagnosis and treatment of HCC.

Indexed as

Lymphocyte CountLymphocyte SubsetsAdultAntigens, CDCarcinoma, HepatocellularFemaleFlow CytometryHumansImmunophenotypingLiver NeoplasmsMaleMiddle AgedPrognosisAntigens, CDCD19+CD3+CD4+hepatocellular carcinomaNK cells

Identifiers

PMID27813499
PMCPMC5363604
OpenAlexW2546464260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.